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Botulinum Toxin for the Face
Amin Amer, Mohamed Amer and Hagar Nofal
Abstract
Botulinum toxin is a corner stone in the facial esthetics. It has been used for 
decades for various medical and esthetic indications. Botulinum toxin is a neuro-
toxin that interferes with the transmission at the neuromuscular/neurosecretory 
junctions by inhibiting the release of acetylcholine. An in depth knowledge of  
the functional anatomy of facial muscles is required to obtain the best results of the 
botulinum toxin injections. In this book chapter, a detailed practical guide for the 
FDA approved and the off label uses of botulinum toxin in the face is presented.  
The recently developed new indications are listed. The lengthy experience with 
botulinum toxin injections has proved safety and tolerability of the procedure; how-
ever, the probable complications, and steps for their prevention and  management 
are highlighted.
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Botulinum toxin (BTXN) is an exotoxin produced by the anaerobic, Gram 
positive, spore forming bacteria; Clostridium botulinum. There are seven serotypes 
A-G. A and B serotypes are the ones currently used commercially. The toxin is 
150 kDa polypeptide, formed of heavy chain and light chain bound by heat sensi-
tive disulfide bonds and noncovalent forces. The toxin may be formulated in a 
simple - free from proteins - form e.g. incobotulinum or complexed with proteins 
as hemagglutinin and “nontoxic molecule” to form onabotulinum toxin and 
abobotulinum toxin [1, 2]. It is essential to keep in mind that the different types of 
the toxin are not similar in their biological effects and potencies [1]. The currently 
available formulations are unique, so their doses are not interchangeable, and the 
dose response curves are probably not parallel [3].
1. Mechanism of action
It inhibits the release of acetylcholine (ACh) from nerve endings via cleavage of 
SNARE protein complex responsible for ACh release. Thus it affects the presynaptic 
nerve endings at the neuromuscular junction (NMJ) causing muscle paralysis (main 
site of action) [1], and the cholinergic postganglionic autonomic nerve fibers inner-
vating the eccrine, salivary and tear exocrine glands (neurosecretory junction) [2, 4]. 
This inhibition is reversible within variable periods of time via the regeneration of 
synaptic junctions [1, 4].
Indications:
Despite being widely used for multiple indications, botulinum toxin’s FDA 
approved indications are limited Table 1.






Onabotulinumtoxin (Botox) Yes Cervical dystonia, severe primary axillary 
hyperhidrosis, strabismus, blepharospasm
Abobotulinumtoxin (Dysport) Yes Cervical dystonia, blepharospasm
Incobotulinumtoxin (Xeomin) Yes Cervical dystonia, blepharospasm
Rimabotulinumtoxin 
#(Myobloc)
No Cervical dystonia, blepharospasm
^Upper limb spasticity, chronic migraine, overactive bladder and urinary incontinence.
Table 1. 












Procerus: Intramuscular, single injection point, 
perpendicular to the skin, 2–4 U [3]
Corrugator: Intramuscular 1–3 injection points at each 
side, First injection point 0.5–1 cm above the medial orbital 
rim, 2nd injection point 1 cm above and lateral to 1st 
injection point, 2–4 U/ point [3]
Lateral canthal 
lines (Crow’s feet) 
(Figure 2)
Orbicularis oculi Intradermal or SC injection of the lateral muscle fibers, 
3 injection points 1–2 cm lateral to the orbital rim, 2–5 U/ 
point, total dose is 6–15 U [3, 5].
Forehead Lines1 
(Figure 3)
Frontalis The target is to only soften, not to completely eliminate, 
forehead lines; the patient ideally can still elevate the 
eyebrows to a lesser extent than prior to treatment [1, 3, 6].
Intramuscular or intradermal (especially near eyebrow), 
4–8 injection points in 1–2 rows, start injection with the 
upper lateral fibers to the mid forehead inferiorly (stop 
2 cm above the brow), 2–4 U/point, total 8–25 U [6].
For narrow forehead less injection points and lower doses 
are used.
To maintain neutral brow position and arch the corrugator 
supercilii, procerus and superiolateral fibers of orbicularis 
oculi are treated at the same time or a few days before 
frontalis injection [1, 3].




Intramuscular, 2–3 injection points, 2 U/point [3].
Gummy smile2 Levator labii 
superioris alaeque 
nasi
Intramuscular (at the site of levator labii superioris alaeque 
nasi and zygomaticus minor convergence with the insertion 





Orbicularis oris BTXN injection is recommended for deep rhytides, 
superficial ones need either resurfacing or hyaluronic fillers
Intradermal, 2–5 injection points, 0.5–1 U/ point [3, 6].
Marionette lines Depressor anguli 
oris
Intramuscular, 1–2 points/ side, 2–3 U/ injection point. The 
main injection point is the posterior aspect of the depressor 
anguli oris muscle at the superior margin of the mandible, 
and at least 1 cm lateral to the oral commissure [3, 6].
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2. Storage and reconstitution
The various BTXN products are supplied as lyophilized powder containing vials 






Mentalis muscle Intramuscular, 1–4 injection points 3–5 U/ point.
Masseter 
overactivity 
(square jaw) / 
bruxism
Masseter muscle Intramuscular, 1–6 injection points/ side, 5–15 U/injection. 
Average of 3 points are injected at the center of the masseter 
square at least 1.5 cm from the mandibular border [7], one 
superiorly and 2 inferior and laterally.
Caucasians tends to need lower doses than Asians with 
longer periods of effect. The injection is to be directed at 
the posterolateral corner [6, 8, 9].
Platysmal bands Platysma Only for patients with obvious platysmal bands, and good 
cervical skin elasticity with no or minimal submental 
fat [6].
Intramuscular or deep intracutaneous, typically 2 bands are 
injected at a time with 3 points of injection in each band, 
1–1.5 cm apart, 1–5 U/ injection point, total 15 U/ band and 
30 U/ session [3, 6].
For horizontal neck folds: Superficial intradermal, 1–2 U/ 
point equidistantly in the folds.
Facial asymmetry 
Caused by Bell’s 
palsy
The contralateral active side is injected using small doses 
(1–2 U) of Ona BTXN into muscles of the normally 
functioning side (the zygomaticus, risorius and orbicularis 
oris muscles) and 5–10 U into the masseter muscle [6, 10].
For post Bell’s palsy synkinesis the paralyzed side is injected 
either as four periocular injections or into the affected 
muscles as orbicularis oculi, orbicularis oris and frontalis 
using the total dose of 10–40 units [10, 11].
Acne and Sebum 
production
Excess sebum production: Few reports of BTXN use 
as intradermal (1 cm apart forehead and check) or 
intramuscular injection (five fixed points in the forehead) 
in the forehead for management of excess sebum 
production 2 U/injection site [12].
Acne: one clinical trial has been registered using 1.5–3 U/ 
active lesions. The trial has been terminated with no 
published reports on the results [13]
Gustatory sweating 
(Frey syndrome)
Intracutaneous injections of 4 U /cm2 [14]
Muscles written in bold are the injected muscles. Facial musculature varies between males and females, with 
increased strength and bulk in men. Thus, higher doses and increased number of injection points are generally 
required in men in all regions of the face [5].
1Brow position is lowered with age “brow ptosis”. Glabellar complex injection (20–40 U) lead to immediate lateral 
eyebrow elevation, followed by an entire brow lift that peaked 12 weeks post treatment. This effect is due to the 
toxin diffusion into the lower medial frontalis muscle fibers with subsequent increased tone in the upper and lateral 
frontalis fibers. Forehead lines is recommended to be done simultaneously with brow lift to maintain a neutral 
position for the eye brow [6].
2Exposure of ≥2 mm of the gingiva on smiling [8]. Done for younger patients with strong lip elevator complex [6].
3Youthful face is a heart shape with fullness in the upper part and tapering toward the mandible [1]. It is essential to 
exclude parotid gland hypertrophy either primary or secondary to pathology as Sjögren syndrome or bulimia nervosa 
or parotid gland mass using clinical assessment and CT imaging, or volume loss related masseteric prominence [3, 15].
Table 2. 
Botulinum toxin neuromuscular indications in the face.
Cosmetic Surgery
4
To reconstitute the powdered BTXN, a non- preserved saline, preserved (bacte-
riostatic) saline or lidocaine can be used as a diluent agent, the laters are associated 
with less pain on injection [1, 4].
The reconstituted vial can be used for up to 4 weeks safely if kept frozen at – 
20°C or refrigerated at 4°C [1, 4].
A single vial can be used for multiple patients, as long as there is safe and sterile 
reconstitution and injection techniques are followed [1, 16].
Figure 1. 
Glabellar complex injection. (a) before: Procerus (blue dot) single intramuscular perpendicular to the skin, 
2–4 U, corrugators (black dots): 2 intramuscular injection points 2–4 U/point; first injection point 0.5–1 cm 
above the medial orbital rim, 2nd injection point 1 cm above and lateral to 1st injection point. (b) after.
Figure 2. 
Lateral Canthal lines injections. (a) before: 3 intradermal injection points 1–2 cm lateral to the orbital rim 
2–5 U/ point. (b) After.
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There are variable methods for BTXN reconstitution. 100 U vial of onabotuli-
unum A is commonly reconstituted in 2 cc of the diluent, which means there is 5 U/ 




The key to successful intervention is tailoring the treatment plan to every 
patient’s need and combining different procedures to achieve best outcome [3]. 
Combination with hyaluronic acid fillers is increasingly utilized to optimize 
outcomes. The combined treatment with fillers can be considered for all regions, 
including the upper face [16].
For esthetic indications, the current trend accepted by both patients and physi-
cians is to use BTXN in the least effective dose, injection points, and at longer 
intervals to achieve muscle activity modulation rather than muscle paralysis [3].
Assessment of the muscles should be performed at rest and at maximum muscle 
contraction [5].
Muscular and bony landmarks are to be used to identify the injection points [3].
It is recommended to discuss with the patients the black box warning and to 
document consent [8].
Figure 3. 
Forehead lines injection. 4–8 intramuscular - intradermal near eyebrow - injection points in 2 rows, starting 




1. Removal of makeup
2. Thorough skin cleansing using 70% alcohol before, during, and after injection
3. Topical anesthesia can be used to minimize the pain.
4. Sterile injection technique using 1 ml 30 gauge needle.
3.3 Post treatment instructions and care
1. Ask the patient to frown and smile repeatedly for 30 minutes following injec-
tion to minimize the diffusion outside the injected muscles.
2. Avoid massaging the treated areas within 3 hours after injection to minimize 
diffusion to other non-injected muscles
3. For upper face, avoid bending over or strenuous physical activity (controver-
sial), lying down or sleeping for 3 hours following the injections.
Contraindication [8, 17]:
1. Infection at site of injection.
2. Known hypersensitivity reaction to any of the ingredients (toxin or human 
albumin).
3. Preexisting inflammatory skin condition at site of injection e.g. acne, contact 
dermatitis, atopic dermatitis and psoriasis.
4. Pregnancy (reports of premature delivery no causal relationship was proven) 
or lactation, it is categorized as C drug
5. Neuromuscular disease or patients with preexisting difficulties in swallowing 
or breathing e.g. myathenia gravis, amyotrophic lateral sclerosis and my-
opathies. Those patients are more predisposed for marked muscle weakness, 
dysphagia or respiratory compromise the toxin unmasked subclinical disease 
in some patients, however BTXN injection was used successfully in others.
6. Co-administration with drugs interfering with neuromuscular activity as 
aminoglycosides, lincosamides, cholinesterase inhibitors, curare-like depolar-
izing blockers, succinylcholine, magnesium sulfate, calcium channel blockers, 
quinidine, and polymyxin.
7. Anti coagulant therapy or bleeding disorders.
4. Complications
Neurotoxins treatments are proven to be remarkably safe. All the reported 
adverse events are related to injection techniques, dosage, or volume of injection. 
Allergic reactions are very rarely encountered.
7




Pain Topical anesthetics, lidocaine for vial reconstitution, 
small gauge (30–32) needles and ice packs.
Edema/ Erythema Ice packs application immediately before and after 
injection.
Ecchymosis Avoid the superficial vasculature (proper lightening and 
stretch the skin for better visualization)
Patient counseling regarding the need to stop NSAIDs, 
aspirin or anticoagulant therapy prior to injection for 
≤1 week.
Headache Those at risk can receive prophylaxis acetaminophen.
Neutralizing antibodies They block the pharmacologic activity of the treatment 
affecting 0.3–6% of patients, its incidence is much 
higher in patients receiving toxin treatments for medical 
indications. BTXN-B products are more immunogenic 
than BTXN-A. It is controversial whether there is 
cross reactivity across different serotypes of the toxin, 
however it is worth trying to shift the patient to another 
serotype e.g. from BTXN-A to BTXN-B as a solution for 
neutralizing antibodies.
Procedure specific
Glabellar complex Eyelid ptosis due to toxin diffusion through the orbital 
septum, paralyzing the levator palpebrae superioris 
muscle, specially when injecting the mid pupillary line 
1 cm above the bony supraorbital rim to obtain horizontal 
brow.
Avoided by the lateral corrugator muscle subdermal 
injection and do not inject within a 1-cm distance above 
the superior orbital rim.
It is treated with α-adrenergic eye drops, such as 
apraclonidine or phenylephrine eye drops.
Frontalis • Brow ptosis due to overtreatment of the frontalis 
muscle. Avoided by keeping the lower most injection 
points 1.5 cm above the brow.
• Excessive lateral brow elevation “Quizzical” brows 
due to central fibers treatment, while the lateral fibers 
inadequately treated causing lateral brow elevation.
Crow’s feet • Ectropion, diplopia, or lateral lower eyelid drooping 
due to injection of the lateral rectus muscle so avoid 
deep intramuscular injection within 1 cm from the 
lateral bony orbit
• Upper lip ptosis due to injection into zygomaticus 
muscle. This can be avoided by not injecting during 
smiling and do not follow the lines inferiorly.
Masseter hypertrophy • Salivary gland enlargement
• Smile limitation and/or asymmetry which is avoided 
by injecting into the square-shaped safe area that is 
bounded by a line joining the oral commissure to the 
ipsilateral earlobe superiorly, the mandibular border 
inferiorly and the anterior and posterior borders of the 
muscle identified while patient grinds on his/her teeth.
Platysma Dysphagia, hoarseness, weakness of the flexors of the 
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